Funding Opportunity RFA-MH-20-200 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.

Funding Opportunity RFA-DK-18-025 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.

Funding Opportunity RFA-DK-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCCfor studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control.?The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.

Funding Opportunity RFA-DK-18-024 from the NIH Guide for Grants and Contracts. The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics into strong postdoctoral appointments that are focused on K, U or H research. It is anticipated that successful completion of this phased award will make the individual highly competitive for a subsequent NIDDK award (e.g., K99/R00, R01). Opportunities for career development activities relevant to their long-term career goals of becoming independent researchers will be provided. Graduate students who are already involved in K, U, or H research are encouraged to apply for the NIDDK F31 (PA-18-671). This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor

Notice NOT-HS-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-021 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-171 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.

Notice NOT-AA-19-006 from the NIH Guide for Grants and Contracts

Notice NOT-MD-19-019 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-067 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-002 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-019 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-20-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application to continue a Connectome Coordination Facility.The competition is limited to the R24 awardee of RFA-MH-15-750.The goal of this award is to (1) maintain a central data repository for Human Connectome data; (2) provide a helpdesk service to answer questions from investigators who are trying to collect data that are compatible with the existing Human Connectome data; and (3) to serve, in a limited capacity, to check quality control and harmonize data from existing Connectome awardees.

Funding Opportunity RFA-HL-20-012 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).

Funding Opportunity RFA-HL-20-011 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).

Notice NOT-DC-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-065 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-066 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-059 from the NIH Guide for Grants and Contracts